Wheezey Cough (Pertussis)
Overview
Pertussis, commonly known as whooping cough, is a highly contagious bacterial infection of the respiratory tract caused by Bordetella pertussis. The classic “whoop” may be absent in many patients, particularly infants and adults, leaving a persistent, wheezy cough as the dominant symptom—often described as a “wheezey cough.”
Who it affects: Everyone can be infected, but the disease is most severe in infants younger than 6 months and in individuals with weakened immune systems. Adolescents and adults frequently experience a milder, cough‑predominant illness that can still spread the bacteria.
Prevalence: In the United States, the CDC estimates ~30,000–50,000 pertussis cases reported each year, but the true incidence is likely higher because many cases go undiagnosed (CDC, 2023). Globally, the WHO records >14 million cases annually, with the highest burden in low‑ and middle‑income countries where vaccination coverage is incomplete.
Symptoms
Pertussis typically follows three clinical stages. Not every patient experiences all phases.
1. Catarrhal stage (1‑2 weeks)
- Low‑grade fever (often <38 °C/100.4 °F)
- Runny nose and mild sore throat
- Headache and mild malaise
- Occasional mild cough – the first sign of the disease
2. Paroxysmal stage (1‑6 weeks, may last up to 10 weeks)
- Severe, repetitive coughing fits lasting from seconds to minutes
- Wheezey, barking cough that may sound like asthma
- Post‑tussive vomiting (vomiting after a coughing bout)
- Inspiratory “whoop” – high‑pitched sound on inhalation (more common in children)
- Exhaustion and facial flushing after paroxysms
- Chest discomfort or mild rib pain from repeated contractions
3. Convalescent stage (2‑3 months)
- Gradual decline in cough frequency
- Persistent, mild cough that may be triggered by cold air, exercise, or irritants
- Episodes can recur for months, especially if the patient has a pre‑existing lung condition.
Note: Infants may present without the classic whoop; instead, they have apnea (pause in breathing) and may look “wheezy” without overt coughing.
Causes and Risk Factors
Cause: Pertussis is caused by the gram‑negative bacterium Bordetella pertussis. The pathogen attaches to ciliated respiratory epithelium and releases toxins (pertussis toxin, tracheal cytotoxin) that damage the lining, impair mucociliary clearance, and trigger intense coughing.
Key risk factors
- Inadequate vaccination: Failure to receive the full DTaP series in childhood or the Tdap booster in adolescence/adulthood.
- Close contact with infected individuals: Household members, daycare settings, schools, and health‑care facilities.
- Age: Infants <6 months old are at highest risk of severe disease and complications.
- Immunocompromised state: HIV, chemotherapy, organ transplantation.
- Pregnancy: Pregnant women are more susceptible and can transmit the infection to newborns.
- Smoking & respiratory comorbidities: Asthma, COPD, or chronic bronchitis increase susceptibility and may mask classic signs.
Diagnosis
Because the wheezy cough of pertussis mimics asthma, bronchitis, or viral infections, a thorough history and targeted testing are essential.
Clinical evaluation
- Detailed exposure history (vaccination status, recent contacts).
- Chronology of cough (duration > 2 weeks, paroxysmal nature).
- Physical exam: inspiratory whoop, post‑tussive vomiting, or prolonged expiratory wheeze.
Laboratory tests
- PCR (polymerase chain reaction) of nasopharyngeal swab: Most sensitive in the first 3 weeks; detects bacterial DNA.
- Culture: Gold standard but less sensitive (≈50‑60 %); useful for antibiotic susceptibility.
- Serology: Measurement of pertussis toxin IgG; helpful after 2‑3 weeks when PCR sensitivity wanes.
Additional investigations
- Chest X‑ray: Usually normal; may show hyperinflation if complications develop.
- Complete blood count: May reveal lymphocytosis (particularly in infants).
Treatment Options
Treatment goals are to eradicate the bacteria, reduce cough severity, prevent transmission, and avoid complications.
Antibiotic therapy
- Azithromycin 10 mg/kg on day 1, then 5 mg/kg on days 2‑5 (preferred for children) – short course, excellent compliance.
- Clarithromycin 7.5 mg/kg bid for 5 days (alternative).
- Erythromycin 40‑50 mg/kg/day in four divided doses for 14 days (historically first‑line, but GI side‑effects limit use).
- For macrolide‑resistant strains, trimethoprim‑sulfamethoxazole or fluoroquinolones** (adults only) may be considered.
Antibiotics are most effective when started within the first 2 weeks of cough. Even when started later, they reduce infectiousness.
Supportive care
- Hydration and humidified air to soothe irritated airways.
- Frequent small meals to prevent vomiting after coughing fits.
- Use of a cool‑mist vaporizer for infants (avoid hot water bottles).
- Analgesics/antipyretics (acetaminophen or ibuprofen) for fever and discomfort.
- Hospitalization for infants <1 month, severe apnea, or respiratory distress.
Adjunctive measures
- Bronchodilators (e.g., albuterol) – may help if wheeze is due to bronchospasm, but they do not treat the underlying infection.
- Corticosteroids – not routinely recommended; may be used if there is a coexisting asthma exacerbation.
Living with Wheezey Cough (Pertussis)
Even after treatment, the cough can linger for weeks to months. Below are practical tips to manage daily life.
- Stay hydrated: Warm teas, broth, and water keep secretions thin.
- Protect your throat: Avoid smoking, second‑hand smoke, and strong fragrances.
- Control triggers: Cold air, dust, and allergens can provoke cough bouts; use a scarf or mask in cold weather.
- Sleep positioning: Elevate the head of the bed or use extra pillows to reduce nighttime coughing.
- Nutrition: Small, frequent meals reduce post‑tussive vomiting; incorporate soft foods (applesauce, yogurt).
- Physical activity: Light activity is fine, but avoid high‑intensity exercise until cough frequency declines.
- Monitor mental health: Persistent coughing can cause anxiety or social embarrassment; consider counseling or support groups.
- Follow‑up: Keep scheduled appointments to ensure cough is improving and to assess for complications.
Prevention
Vaccination remains the cornerstone of pertussis prevention.
- DTaP series: Five doses administered at 2, 4, 6, 15‑18 months, and 4‑6 years.
- Tdap booster: One dose at 11‑12 years; then a booster every 10 years for adults.
- Maternal vaccination: Tdap during each pregnancy (27‑36 weeks gestation) confers passive immunity to newborns.
- Post‑exposure prophylaxis: Close contacts of a confirmed case should receive a single dose of azithromycin or erythromycin within 21 days of exposure.
- Hygiene measures: Hand washing, covering coughs, and avoiding close contact with ill individuals.
Complications
If untreated or poorly managed, pertussis can lead to serious outcomes.
- Infants: Apnea, pneumonia, seizures, encephalopathy, and death (case‑fatality ≈ 5‑10 % in <6‑month olds).
- Adults: Rib fractures, urinary incontinence, syncope, and secondary bacterial pneumonia.
- Pregnant women: Preterm labor or low‑birth‑weight infants.
- Long‑term cough: Can persist >12 weeks (post‑pertussis cough syndrome), impairing quality of life.
When to Seek Emergency Care
- Difficulty breathing or rapid, shallow respirations.
- Apnea (a pause in breathing) or a significant drop in oxygen saturation.
- Vomiting blood or persistent vomiting that prevents keeping fluids down.
- Severe chest pain that does not improve with rest.
- Confusion, lethargy, or a sudden change in mental status.
- High fever (>39.5 °C / 103 °F) that does not respond to antipyretics.
- Signs of dehydration (dry mouth, no tears, reduced urine output).
Prompt medical attention can prevent life‑threatening complications, especially in infants and high‑risk adults.
References: CDC. Pertussis (Whooping Cough) – 2023 | WHO. Pertussis Fact Sheet – 2022 | Mayo Clinic. Whooping cough – 2024 | NIH National Library of Medicine. Pertussis – 2023 | Cleveland Clinic. Pertussis (Whooping Cough) – 2024.
```